Navigation Links
Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs

DALLAS, April 9, 2015 /PRNewswire/ -- adds "PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs" to its store.

The report "PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs" applies our proprietary ranking methodology to compare the competitive positions of 35 mid-cap biotechnology companies on 14 financial metrics. These companies are analyzed based on their financial performance, research and development (R&D) spending, capital structure, and firm utilization to illustrate the different strategies they are using to increase value for their shareholders and create a competitive advantage.

In addition to the financial metrics, this report provides an overview of the biotech sector growth rates, and discusses the regulatory approvals that occurred in 2014, along with our forecast sales outlook for each drug. We also examine how the patent cliff will impact the industry moving forward, along with deals and licensing activity, and the prospects for niche/orphan drugs. Lastly, we use our proprietary database tools to determine the Net Present Value (NPV) of both marketed and clinical pipeline assets and their future profits and cash flows.

Key Questions Answered covered in this report include: What specific strategies are these innovative biotech companies employing to gain market share?; What therapeutic areas are these biotech companies focusing their R&D spending?; Which trends will affect the biotech sector moving forward?; How does my pipeline and commercialization strategy match up against the competition?; What specific business development activities are taking place, in terms of partnerships or M&A?; What particular enabling technologies and drug platforms are these biotech companies developing?; How are these biotech companies maximizing their capital spend to gain a competitive advantage?

The combined total revenues for the peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014, representing a Compound Annual Growth Rate (CAGR) of 21.9% Companies analysis discussed in this PharmaLeaders: Mid-Cap Biotechnology Benchmark Report - Sales Forecasts and Product Valuations of Innovative Biotechs report include Acadia, Actelion, Alexion, BioMarin, Cubist, Incyte, Medivation, Pharmacyclics, Regeneron and Vertex. Order a Purchase copy of this report @ . (This is a premium report priced at US$3995 for a single user License.)


  • This report provides analysis of the key drivers and trends shaping the biotechnology sector; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation
  • This report offers a deep dive into the synergies behind partnering and acquisition activity
  • FDA expedited review - drugs approved by Fast Track, Breakthrough, Priority Review, and Accelerated approval pathways
  • Six-year forecasts for key drugs approved in 2014; Net Present Value (NPV) for key drugs approved in 2014.

Reasons to buy 

  • Analyze and track the strategies that these drug companies are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
  • Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, equity investment or takeover
  • Independent source to benchmark your company's performance against a similar peer group to assess areas of strength/weakness

Table of Contents 

1 Table of Contents 

2 Introduction 

2.1 Report Scope

2.2 Companies Covered

2.3 Upcoming Reports

2.4 Recently Published Reports

3 Market Dynamics 

3.1 Sector Fundamentals

3.2 FDA Approved 41 New Drugs in 2014

3.3 Orphan Drugs: No Longer a Rare Opportunity

3.4 FDA Approved 27 New Drugs in 2013

3.5 Patent Cliff to Erode $65 Billion in Sales by 2019

4 Collaboration and Acquisition Strategies 

4.1 Deals Landscape

4.2 M&A Analysis

4.3 Licensing and Partnership Deals

5 Financial Management 

5.1 Revenue

5.2 Year-to-Year Revenue Growth

5.3 Operating Income

5.4 Gross Profit Margin

5.5 Expense Performance Metrics

5.6 Liquidity and Valuation Metrics

6 Company Analysis 

6.1 Acadia

6.2 Actelion

6.3 Alexion

6.4 BioMarin

6.5 Cubist

6.6 Incyte

6.7 Medivation

6.8 Pharmacyclics

6.9 Regeneron

6.10 Vertex

7 Future Outlook 

8 Appendix 

Explore more reports on Biotechnology at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441

SOURCE RnR Market Research
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
2. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
3. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
4. Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
5. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
6. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
7. TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
8. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
9. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
10. NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand
11. Cytos Biotechnology Ltd Announces the Completion of Patient Enrolment in the On-going Phase 2b Study of CYT003 for the Treatment of Allergic Asthma
Post Your Comments:
(Date:11/11/2019)... ... ... A gifted actor and generous philanthropist, Laurence Fishburne, will introduce a new ... "Behind The Scenes." The growth of health management tools in health facilities is critical ... will focus on which tools are the most successful in allowing these professionals to ...
(Date:11/9/2019)... ... November 08, 2019 , ... As ... (PHA) sets aside a day to help raise awareness and improve diagnosis of ... (CTEPH). Unlike some forms of PH, CTEPH has several treatment options, including a ...
(Date:11/9/2019)... ... November 09, 2019 , ... ... why it’s the hallmark of much-loved, fictional British characters, like James Bond and ... what’s not to admire about calm stoicism, even in the most perilous and ...
Breaking Medicine Technology:
(Date:11/11/2019)... Pa. (PRWEB) , ... November 11, 2019 , ... ... equipment, announced the shipment of two (2) Gruenberg Depyrogenation Sterilizers to ... These pharmaceutical sterilizers have maximum temperature ratings of 280°C with work chamber dimensions ...
(Date:11/11/2019)... ... November 11, 2019 , ... Dr. John V. Prunskis, co-founder and ... Human Services’ (HHS) Pain Management Best Practices Task Force (Pain Task Force) met last ... in follow up to the HHS Pain Task Force’s final report that was submitted ...
(Date:11/9/2019)... ... November 08, 2019 , ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization ... that provide free special education law and advocacy assistance to families and patients in ... also honored the work of contributions of Blaine (“Fin”) Fogg, who was a member ...
(Date:11/7/2019)... ... November 07, 2019 , ... ALZYN, LLC today announced ... to Watch in 2019.’ , “The Silicon Review 50 Best Companies to Watch ... and Business world than others, and winning a spot on this list indicates the ...
(Date:11/7/2019)... (PRWEB) , ... November 07, 2019 , ... ... and co-founder of Ignite and Expand got together on the Shamangelic Healing ... number of downloads skyrocketed. With a trending focus on learning ways to use ...
Breaking Medicine News(10 mins):